DevPro Biopharma
DevPro Biopharma is a private clinical research and development accelerator that partners with pharmaceutical companies and VCs to design, develop, and deliver respiratory molecules into globally approved medicines, with deep expertise in metered-dose inhaler technology and regulatory submissions across FDA, EMA, and PMDA jurisdictions.
- Company typePrivate
- Founded2020
- HeadquartersBasking Ridge, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What DevPro Biopharma does
DevPro Biopharma is a private clinical research and development accelerator founded in 2020 and headquartered in Basking Ridge, New Jersey. The company designs, develops, and delivers molecules into respiratory medicines through strategic partnerships with pharmaceutical companies and venture capital firms, offering full-lifecycle development from concept through global regulatory approvals with agencies including the FDA, EMA, PMDA, MHRA, Health Canada, TGA, and NMPA. Headcount is reported at 11-50 employees.
The firm's technical platform is focused on respiratory therapeutics, with proprietary development efforts in metered-dose inhaler (MDI) technology. Notable technology components include eco-friendly HFO-1234ze propellant inhalation solutions developed in partnership with Bespak, and next-generation low-emission respiratory inhaler technology powered by Honeywell. The team's historical track record includes contributions to more than 50 approved products or label expansions over the past 30 years across multiple therapeutic areas, including flagship respiratory products BEVESPI AEROSPHERE and BREZTRI AEROSPHERE developed with AstraZeneca. The active clinical pipeline targets COPD, asthma, pulmonary hypertension, idiopathic pulmonary fibrosis, progressive pulmonary fibrosis, cystic fibrosis, and alpha-1 antitrypsin deficiency.
DevPro operates a B2B, sales-led go-to-market model, generating revenue through professional services for clinical development and licensing/milestone arrangements for co-developed new molecular entities. Pricing is quote-based and not publicly disclosed. The company does not commercialize end products directly; rather, distribution of approved therapies is handled through pharmaceutical partners' existing global networks. Customer segments center on pharmaceutical companies and VC investors seeking de-risked assets and development expertise, with respiratory disease patients as the end-user beneficiaries of the resulting medicines.
DevPro Biopharma firmographics
Firmographics- Name
- DevPro Biopharma
- Legal name
- DevPro Biopharma
- Website
- https://devprobiopharma.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- DevPro Biopharma is a private clinical research and development accelerator that partners with pharmaceutical companies and VCs to design, develop, and deliver respiratory molecules into globally approved medicines, with deep expertise in metered-dose inhaler technology and regulatory submissions across FDA, EMA, and PMDA jurisdictions.
- Ownership category
- akta.pro rank
DevPro Biopharma industry classification
Industry- Product category
- Pharmaceutical Clinical Development Services
- NAICS
- Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Pulmonology & Allergy Specialty Pharmaceuticals (HLAIACAF)
- akta.pro secondary industry
- CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD)
Keywords
Where DevPro Biopharma is headquartered
LocationHeadquarters
- HQ city
- Basking Ridge
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
DevPro Biopharma business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Strategic Partnership Development: Revenue generated through strategic partnerships with pharmaceutical companies and VCs for co-development of new molecular entities, with potential milestone payments and licensing arrangements
- Clinical Development Services: Full development activities from concept through regulatory approvals, creating value through de-risked assets, accelerated timelines, and lower costs for partners
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
DevPro Biopharma product offering
Product offeringCore offering
DevPro Biopharma is a clinical research and development accelerator that partners with pharmaceutical companies and venture capital firms to design, develop, and deliver molecules into approved medicines. Its core work spans the full clinical development lifecycle for respiratory therapeutics, including clinical trials, global regulatory submissions, and co-development of eco-friendly inhalation technologies such as HFO-1234ze-based metered dose inhalers.
Product overview
DevPro Biopharma is a clinical development services company focused on bringing molecules into medicines through innovation, flexibility, and efficiency. The company offers development expertise spanning from concept through global regulatory approvals, with a focus on respiratory therapeutics. Their portfolio includes contributions to approved products such as BEVESPI AEROSPHERE® and BREZTRI AEROSPHERE™, as well as development of next-generation low-emission respiratory inhalers. DevPro's clinical development platform enables strategic partnerships with pharmaceutical companies and VCs to de-risk assets, accelerate timelines, and lower development costs.
Differentiator
Problem solved
Functional benefit
Products and services
- Clinical Development Services for Respiratory Therapeutics End-to-end clinical research and development services including clinical trial design, execution, regulatory submissions, and global approvals for pharmaceutical and VC partners developing respiratory therapies.
- Next-Generation Low-Emission Respiratory Inhaler An eco-friendly respiratory inhaler platform powered by Honeywell technology with reduced global warming potential, developed as an alternative to traditional CFC inhalers for respiratory drug delivery.
- HFO-1234ze Propellant Inhalation Solution Eco-friendly metered dose inhaler propellant solution using HFO-1234ze developed in partnership with Bespak to address the phase-out of CFC inhalers and meet demand for environmentally responsible respiratory devices.
Quantifiable outcome
- More than 50 approved products or label expansions over 30 years
- +2 more outcomes
Companies that use DevPro Biopharma
Customer profileSegments3 records
Ideal customer profiles2 records
DevPro Biopharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
DevPro Biopharma partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- BespakcoreDevPro Biopharma and Bespak are developing eco-friendly inhalation solutions using HFO-1234ze propellant as a sustainable alternative to CFC inhalers. This partnership addresses the phase-out of CFC inhalers and contributes to the growing demand for environmentally responsible respiratory care devices. The collaboration positions DevPro in the emerging market for next-generation metered dose inhalers.
- HoneywellcoreHoneywell technology powers DevPro Biopharma's next-generation low-emission respiratory inhaler. This partnership enables development of environmentally friendly inhalation solutions with reduced global warming potential. Honeywell's technology expertise combined with DevPro's respiratory development capabilities supports innovation in sustainable respiratory drug delivery.
Scale indicators1 record
Recent moves3 records
Expansion highlights5 records
DevPro Biopharma competitors and assessment
Company assessmentBroad incumbents
- Medpace: Mid-to-large CRO with strong specialty pharma and biotech focus, known for full-service clinical development. Comparable outsourced development model targeting pharma/biotech sponsors across therapeutic areas.
- IQVIA: Largest global CRO and life sciences services provider offering end-to-end clinical development across all therapeutic areas. Sets the competitive benchmark on scale, geographic reach, and integrated services that DevPro competes against.
- ICON plc: Large global CRO providing outsourced drug development and clinical research services. Competes with DevPro for pharma outsourced development work, particularly on multi-region respiratory programs.
- Syneos Health: Clinical and commercial solutions provider offering biopharma development services including clinical research and post-launch commercialization. Comparable outsourced model serving pharma and biotech sponsors.
Direct peers
- Worldwide Clinical Trials: Mid-size global CRO with deep specialty pharma and respiratory therapeutic expertise, offering outsourced clinical development services to pharma and biotech sponsors. Closely comparable in size, therapeutic focus, and B2B development-services model.
- Kindeva Drug Delivery: Specialty CDMO focused on inhaled drug delivery and combination drug-device development (formed from the merger of 3M Drug Delivery Systems and Vectura). Directly comparable for inhaled respiratory development capabilities and propellant/device expertise.
- Hovione: Contract development and manufacturing organization with strong inhalation and respiratory drug formulation capabilities. Comparable as an outsourced development partner for inhaled therapeutics spanning formulation through clinical supply.
- Aptar Pharma: Global leader in drug delivery device development including metered dose inhalers, dry powder inhalers, and nasal sprayers. Directly comparable for inhaler device technology and respiratory drug delivery partnerships.
Emerging players
- Verona Pharma: Late-stage clinical biopharma focused on respiratory diseases including COPD and cystic fibrosis. Comparable respiratory therapeutic focus and inhaled drug development, though as an asset-owning sponsor rather than a services partner.
- Insmed: Late-stage respiratory biopharmaceutical company developing inhaled therapies for serious lung diseases. Comparable respiratory therapeutic focus and inhalation-based development approach as a peer sponsor in the pulmonology space.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights5 records
Customer concentration
DevPro Biopharma social profiles
Digital presenceDevPro Biopharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
DevPro Biopharma leadership team
Management profileNumber of profiles
DevPro Biopharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
DevPro Biopharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about DevPro Biopharma
What does DevPro Biopharma do?
DevPro Biopharma is a clinical research and development accelerator that partners with pharmaceutical companies and venture capital firms to design, develop, and deliver molecules into approved medicines. Its core work spans the full clinical development lifecycle for respiratory therapeutics, including clinical trials, global regulatory submissions, and co-development of eco-friendly inhalation technologies such as HFO-1234ze-based metered dose inhalers.
Is DevPro Biopharma a public or private company?
DevPro Biopharma is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was DevPro Biopharma founded?
DevPro Biopharma was founded in 2020. It employs 11 to 50 people.
Where is DevPro Biopharma based?
DevPro Biopharma is headquartered in Basking Ridge, United States, in the North America region.
How does DevPro Biopharma make money?
Two revenue lines are on record. Strategic Partnership Development is the primary driver. The others are clinical Development Services.
Who are DevPro Biopharma's main competitors?
Broad incumbents on record are Medpace, IQVIA, ICON plc and Syneos Health. Direct peers are Worldwide Clinical Trials, Kindeva Drug Delivery, Hovione and Aptar Pharma. Emerging players are Verona Pharma and Insmed.
Does DevPro Biopharma have an API?
No public API is recorded for DevPro Biopharma.
What industry is DevPro Biopharma in?
DevPro Biopharma's product category is Pharmaceutical Clinical Development Services. Its primary akta.pro industry code is HLAIACAF, Pulmonology & Allergy Specialty Pharmaceuticals, with a secondary code of HLAIALAD, CMC & Pharmaceutical Development (Formulation/Process/Analytical Development). Its NAICS code is 5417 and its SIC code is 8731.